ArticlePLOS global public health2022
Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey.
Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Knowledge, awareness, and perception of healthcare professionals towards Long COVID in Nigeria.Frontiers in public health · 2026Article
- COVID19 Sero-epidemiology and vaccine uptake in two Southern Nigerian clinics.PLOS global public health · 2026Article
- Seroprevalence and molecular detection of SARS-CoV-2 among apparently healthy healthcare workers and patients in a Nigerian tertiary hospital.BMC infectious diseases · 2025Article
- Genomic diversity and surveillance of SARS-CoV-2 in Nigeria.BMC genomics · 2025Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Coronavirus Disease 2019 Vaccination Trends: Findings from Surveillance Conducted at First Antenatal Care Visits in Kenya, Nigeria, Malawi, Mozambique, Uganda, and Zambia, 2021-2022.The American journal of tropical medicine and hygiene · 2025Article
- Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.Scientific reports · 2025Article
- Negotiating cohabitation in a Nigerian abattoir: One Health perspectives of human-animal-ecosystem interactions examined in the light of the SARS-CoV-2 pandemic.One health outlook · 2025Article
- COVID-19 TESTING PERFORMANCE AND STRATEGIES FOR RAPID SCALE UP OF LABORATORY CAPACITY IN A PUBLIC HEALTH EMERGENCY IN A RESOURCE-CONSTRAINED SETTING: THE SARS-COV-2 NIGERIA RESPONSE EXPERIENCEJ.Annals of Ibadan postgraduate medicine · 2025Article
- Social vulnerability index associated with higher COVID-19 seroprevalence in Nigeria.Global health action · 2024Article
- Private sector tuberculosis care quality during the COVID-19 pandemic: a repeated cross-sectional standardised patients study of adherence to national TB guidelines in urban Nigeria.BMJ global health · 2024Article
- Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022.Epidemiology and infection · 2023Article
- High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo.Open forum infectious diseases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in four Nigerian states (Enugu, Gombe, Lagos, and Nasarawa) to estimate age-stratified prevalence of SARS-CoV-2 antibodies. All individuals in sampled households were eligible for interview, blood draw, and nasal/oropharyngeal swab collection. We additionally tested participants for current/recent malaria infection. Seroprevalence estimates were calculated accounting for the complex survey design. Across all four states, 10,629 (96·5%) of 11,015 interviewed individuals provided blood samples. The seroprevalence of SARS-CoV-2 antibodies was 25·2% (95% CI 21·8-28·6) in Enugu State, 9·3% (95% CI 7·0-11·5) in Gombe State, 23·3% (95% CI 20·5-26·4) in Lagos State, and 18·0% (95% CI 14·4-21·6) in Nasarawa State. Prevalence of current/recent malaria infection ranged from 2·8% in Lagos to 45·8% in Gombe and was not significantly related to SARS-CoV-2 seroprevalence. The prevalence of active SARS-CoV-2 infection in the four states during the survey period was 0·2% (95% CI 0·1-0·4). Approximately eight months after the first reported COVID-19 case in Nigeria, seroprevalence indicated infection levels 194 times higher than the 24,198 officially reported COVID-19 cases across the four states; however, most of the population remained susceptible to COVID-19 in October 2020.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.